This trial is testing a combination of drugs to see if they are effective in treating patients with lung cancer that has spread to other parts of the body. The drugs may work by blocking enzymes needed for cell growth.
- Non-Small Cell Lung Cancer
- Stage IV Lung Cancer
- Stage IVA Lung Cancer
- Stage IVB Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
2 Primary · 3 Secondary · Reporting Duration: From start of treatment to time of progression or death, whichever occurs first, assessed at 1 year
1 Treatment Group
Treatment (osimertinib, MRX-2843)
1 of 1
69 Total Participants · 1 Treatment Group
Primary Treatment: Flt3/MerTK Inhibitor MRX-2843 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 19 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still vacancies for patients to join this experiment?
"As indicated on the clinicaltrials.gov database, this trial is actively enrolling participants and was first introduced to the public on February 24th 2021 with its most recent update occuring on March 8th 2022." - Anonymous Online Contributor
What evidence is there to support the efficacy of Flt3/MerTK Inhibitor MRX-2843?
"Currently, 101 investigations into Flt3/MerTK Inhibitor MRX-2843 are taking place with 17 trials in the final stage. Out of Uniondale, New York several studies on this subject matter have been initiated and a grand total of 4702 locations are running clinical trials for Flt3/MerTK Inhibitor MRX-2843." - Anonymous Online Contributor
Is this a pioneering research project?
"Since 2013, research into Flt3/MerTK Inhibitor MRX-2843 has been ongoing. It was initially sponsored by AstraZeneca in a study involving 603 patients. Following the first trial, it received its Phase 1 & 2 drug approval and is now currently being studied across 1059 cities within 51 nations with 101 active trials." - Anonymous Online Contributor
How many volunteers have participated in this experiment?
"Affirmative. The clinical trial is currently recruiting, as evidenced by the data hosted on clinicaltrials.gov from its inception date of February 24th 2021 and latest update on March 8th 2022. 69 volunteers are being sought across a single site for recruitment." - Anonymous Online Contributor
Could you please expound on the risks of Flt3/MerTK Inhibitor MRX-2843?
"Assessing the safety of Flt3/MerTK Inhibitor MRX-2843 on a scale from 1 to 3, our team at Power have assigned it a score of 1 as this is still in its early Phase 1 trial and there is limited evidence regarding efficacy and safety." - Anonymous Online Contributor